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Curcumin’s role as an antioxidant has been studied in numerous studies and has shown 
potentials as a glycation inhibitor. This study aimed to study curcumin’s ability to inhibit glycation 
of α-crystallin to find out its potentials as an antioxidant for preventing diabetic cataract. The first 
experiment looked at the difference between the sample containing curcumin and the sample 
without curcumin without any incubation period. The fluorescence detection was set at at 37 
degrees Celsius for wavelengths of 325/434 nm, 295/340 nm, 330/415 nm and 370/440 nm 
measuring for N-formylkynurenine, tryptophan, dityrosine and MGO respectively. There was no 
significant difference between the sample containing curcumin and the sample without 
curcumin. The results were the same in the experiment set at same conditions but with 24-hours 
incubation period. The control experiment which was done in the same conditions except with a 
known glycation inhibitor, aminoguanidine hydrochloride. With aminoguanidine hydrochloride, 
there was a significant decrease in the fluorescence compared to its absence. Although there 
were no experiments directly with α-crystallin, the test-run experiments with curcumin and 
aminoguanidine hydrochloride provides evidence that curcumin failed to inhibit glycation of BSA 
and has low probability with successful inhibition of α-crystallin glycation. 
 
Introduction 
Advanced glycation end products are the result of protein glycation and often lead to 
development of several complications in diabetic patients. Early onset of cataracts is one of 
many complications involved.​1​ The development of cataracts is common in people of age 65 or 
older but diabetes can hasten the process through glycation of lens proteins.​2​ When cataracts 
develop and begin to disrupt eyesight, most people residing in United States can easily remove 
it through surgery since cataract surgery is one of the most common surgery in US with an 
overall success rate of 98% or higher.​3​ However, many people in developing countries still 
cannot afford cataract surgery and live with the discomfort until blindness sets on because there 
are no medications available for the disease. To find an alternative to surgery for treating 
cataracts, many different methods have been studied. Among several potential treatment 
methods, antioxidants that inhibit advanced glycation end products have been studied as a way 
to prevent cataracts. Although this is only preventive, it may still be helpful for diabetic patients 
who do not expect to get the surgery to delay the early onset of cataracts. In this research, 
curcumin, an antioxidant, will be studied for its effectiveness in preventing development of 
cataracts due to advanced glycation. 
Aggregation of advanced glycation end products is stimulated by oxidative stress and 
hyperglycemia with diabetes and this aggregation of advanced glycation end products is what 
leads to complications such as cataracts.​ ​Curcumin has been studied in the past with diabetic 
rats for the relationship it may have with the advanced glycation end product levels. The study 
showed that the oxidative stress and cross-linking of collagen decreased and glycation was 
prevented in these diabetic rats.​4​ In this study, the focus is put on the glycation of lens crystallin 
and the role of curcumin as an antioxidant to inhibit the glycation of this protein found in the eye 
that leads to diabetic cataracts.  
Figure 1: Structure of curcumin 
 
 
Specifically, the glycation of α-crystallin found in the lens is common because α-crystallin 
has a relatively long half-life and hence more prone to posttranslational modifications such as 
glycation.​5​ Glycation of α-crystallin results in several problems as it loses its anti-apoptotic 
activities and its function as chaperone protein leading to other protein aggregates.​6​ Curcumin 
which has been found to reduce glycation in diabetic rats will be used with of α-crystallin and 
D-glucose to measure its effectiveness in inhibiting glycation of lens crystallin to prevent 
cataracts.  
As a control experiment, aminoguanidine hydrochloride will be used in place of 
curcumin. Aminoguanidine hydrochloride is a known glycation inhibitor due to its ability to lower 
the effective concentration of glucose or MGO to slow down the glycation. Trial experiments will 
first be conducted with bovine serum albumin (BSA) instead of α-crystallin. This is done to attain 
the correct experimental parameters for α-crystallin and prevent wasting the limited resources. 
In addition, as an alternative for when D-glucose is not significantly glycated in a given 
amount of time, MGO will be used to replace it. MGO is a more powerful glycating agent than 
glucose. 




Figure 3: Structure of D-glucose 
 
 
Figure 4: Structure of MGO (Methylglyoxal) 
 
 
Materials and Methods 
 
Curcumin​ from ​Curcuma longa​ (Turmeric)​, MGO, BSA and DMSO were the main materials used 
in determining the influence of curcumin in inhibiting glycation. All materials were purchased 
from Sigma Aldrich. To create an MGO solution with a concentration of 50mM, 77 µL of 
filter-sterilized MGO was mixed with 10 mL of PBS (pH 7.4) which acted as a buffer. For the 
protein solution with a concentration of 5 mg/mL, 50 mg of BSA was mixed in 10 mL of buffer. 
Lastly, 0.0037g of curcumin was mixed with 1 mL of DMSO before adding 0.1 mL of this 
solution to 29.9 mL of buffer to create a concentration of 0.05 mM. The purpose of mixing 
curcumin with DMSO first was to aid in better resolution of curcumin in buffer. Different 
combinations of these prepared solutions were pipetted into the microplate to create 6 controls 
and 1 experimental condition. For the experimental solution, 0.1 mL of MGO, 0.1 mL of BSA 
and 0.01 mL of curcumin was pipetted into each well in triplicates. The rest of the 6 control 
samples were missing either BSA, curcumin, MGO, both BSA and MGO, both BSA and 
curcumin or all BSA, MGO and curcumin. All the controls were pipetted in triplicates. In the first 
experiment, the samples were incubated for 24 hours at 21 degrees Celsius and the incubation 
was excluded in the second experiment. To read and measure glycation-related chemical and 
conformational changes, the microplate reader was set at 37 degrees Celsius for 325/434 nm 
(N-formylkynurenine), 295/340 nm (Tryptophan), 330/415 nm (Dityronsine) and 370/440 nm 
(formation of advanced glycation end product). To test what effects were brought by curcumin, 
all conditions were kept the same in the third experiment with 1 mM of aminoguanidine 
hydrochloride replacing the curcumin solution. Aminoguanidine hydrochloride is a known 
glycation inhibitor.  
Results and Discussion 
 





































Graph 9: Glycation progression after incubation in the presence of aminoguanidine 




Graph 10: Glycation progression after incubation in the presence of aminoguanidine 
hydrochloride measured at 325/434 nm. 
 
 
Graph 11: Glycation progression after incubation in the presence of aminoguanidine 




Graph 12: Glycation progression after incubation in the presence of aminoguanidine 




The initial design for this research was to find the glycation inhibition potential of 
curcumin with α-crystallin. The first few experiments with BSA was going to be test runs to find 
out the optimal concentration, incubation period and wavelength for the experiment with 
α-crystallin. However, these experiments with BSA failed to demonstrate curcumin as a 
glycation inhibitor. 
Graphs 1, 2, 3, 4 show insignificant difference in the rate of AGE production between the 
experimental sample containing all MGO, BSA and curcumin and the control sample containing 
just MGO and BSA. As graphs 5, 6, 7, 8 indicate, a 24 hour incubation period did not make 
much difference between the control and experimental samples. Still, a 24 hour incubation 
seem to be effective with detecting a more stable glycation progression as illustrated by the 
relatively constant fluorescence in graphs 5, 6, 7, 8  compared to graphs 1, 2, 3, 4. 
 The control experiment with a known glycation inhibitor, aminoguanidine hydrochloride, 
shows a significant difference in the rate of AGE production between the experimental and 
control samples. Graphs 9, 10, 11, 12 show a significantly lower fluorescence at every 
wavelength for the sample containing aminoguanidine hydrochloride compared to the sample 
not containing it. This control experiment supports the failure of inhibiting glycation with 




This series of experiments failed to support or reject the hypothesis that curcumin 
inhibits the glycation of α-crystallin. This is because there were no actual experiments with 
curcumin and α-crystallin to draw conclusions from. However, experiments with curcumin and 
BSA which were supposed to be test-runs provided enough evidence that there is a low 
probability that curcumin will prevent glycation of α-crystallin. There were no significant 
decrease in the fluorescence for the sample containing curcumin compared to the sample 
without curcumin. The results remained unchanged even after a 24 hour incubation. 
 The experiment under same conditions with aminoguanidine hydrochloride as the 
glycation inhibitor showed a significant decrease in the fluorescence for the sample containing 
aminoguanidine hydrochloride compared to the sample without it. This helped determine that it 
was curcumin that failed to cause decrease AGE production. 
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